There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Haemonetics (HAE – Research Report) and Optinose (OPTN – Research Report) with bullish sentiments.
Haemonetics (HAE)
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Haemonetics, with a price target of $114.00. The company’s shares closed last Tuesday at $92.61, close to its 52-week high of $95.26.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Haemonetics has an analyst consensus of Strong Buy, with a price target consensus of $109.50, a 20.4% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $115.00 price target.
See the top stocks recommended by analysts >>
Optinose (OPTN)
Lake Street analyst Thomas Flaten maintained a Buy rating on Optinose today and set a price target of $3.00. The company’s shares closed last Tuesday at $1.23, close to its 52-week low of $0.90.
According to TipRanks.com, Flaten is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Optinose with a $3.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HAE:
